-
Compete with HAE's first oral therapeutic drug!
Time of Update: 2021-08-29
Recently, BioCryst launched Orladeyo, the first oral treatment for hereditary angioedema (HAE), and the North Carolina-based biotechnology company has priced Orladeyo lower than its main competitors, Takeda and CSL Behring .
-
Phase III study of CXCR4 inhibitor fails, Fosun Pharma has China rights
Time of Update: 2021-08-29
Polyphor Dahuan Technology Platform (Source: Polyphor AG)The FORTRESS study (POL6326-009) is a randomized, open-label, positive-controlled, international multicenter phase III study, which aims to evaluate intravenous balixafortide combined with eribulin versus eribulin monotherapy in the treatment of HER2-negative local Efficacy, safety and tolerability of recurrent or metastatic breast cancer .
-
Merck voluntarily revokes Keytruda's accelerated approval for third-line treatment of gastric cancer in the U.S.
Time of Update: 2021-08-29
CompileriverOn July 1, US Eastern time, Merck’s official website announced that it would voluntarily withdraw an indication previously approved by the FDA for Keytruda, specifically: for the treatment of recurrent locally advanced or metastatic gastric or gastroesophageal junction (GEJ) glands Cancer patients whose tumors express PD-L1 [combined positive score (CPS) ≥ 1] .
-
Faith Medicine's AAV gene therapy is approved for clinical treatment of hemophilia B patients
Time of Update: 2021-08-29
BBM-H901 injection is an AAV gene therapy drug developed by Faith Medicine, which aims to introduce human coagulation factor IX (Factor IX, FIX) gene into hemophilia B patients through intravenous administration, thereby improving and maintaining the patient's body for a long time.
-
New regulations for continuing education of licensed pharmacists are here
Time of Update: 2021-08-29
In accordance with the requirements of the "Draft of Opinions", the pharmacy professional and technical personnel who participate in continuing education through the following methods will be included in the continuing education hours of the year:1.
-
In 2021, the second batch of newly-added packaging quantities drug online procurement notice is released!
Time of Update: 2021-08-29
On July 7, 2021, drug information will be pushed to medical institutions through the "Shanghai Pharmaceutical Purchasing Service and Supervision Information System" (hereinafter referred to as the Sunshine Platform), and price negotiation will take effect on July 9 .
-
Osaikang: ASKC852 Tablets Subsidiary Obtained Clinical Trial Approval Notice
Time of Update: 2021-08-29
On June 28, Osaikang announced that its subsidiary, ASKC852 tablets, has obtained a notice of clinical trial approval.
ASKC852 tablets are innovative drugs registered and classified as category 1, and are brand-new small-molecule immunomodulatory drugs .
-
Innovent announces a license agreement with Synaffix for antibody-conjugated drug technology
Time of Update: 2021-08-29
According to the terms of the agreement, Synaffix will provide the necessary proprietary ADC technologies, including GlycoConnect™, HydraSpace™, and a certain linker-toxin under its toxSYN™ platform, enabling Innovent to quickly develop its own antibody based on its own antibody and have the best in class Potential ADC candidate molecule .
-
Hutchison Pharmaceuticals and Epizyme cooperate to develop and commercialize TAZVERIK in Greater China
Time of Update: 2021-08-29
Hutchison Medicine will also participate in Epizyme's global registration study of TAZVERIK® combined with R2 in the treatment of second-line follicular lymphoma, the EZH-302 study, and lead the study in Greater China .
-
Beijing Municipal Medical Insurance Bureau issued a document to clarify the scope of clinical trials and medical insurance payment
Time of Update: 2021-08-29
" Medical Network, August 11, recently, the Beijing Municipal Medical Insurance Bureau issued the "Notice on Further Clarifying the Scope of Medical Insurance Fund Payment for Medical Expenses Related to Drug Clinical Trials", which is the first nationwide to clarify the relationship between clinical research and medical insurance payments .
-
Zerro salmon triple seeding technology has succeeded
Time of Update: 2021-08-29
In order to fully guarantee the controllable provenance, the Salmon and Trout Genetic Breeding Innovation Team of the Heilongjiang Fisheries Research Institute has carried out the seed production of the triploid Salmon .
-
AstraZeneca's second-generation PARP inhibitor AZD5305 has been applied for clinical application in China
Time of Update: 2021-08-29
Text | pick up shellsOn July 6, the CDE official website showed that the clinical application of AstraZeneca's second-generation PARP (highly selective PARP1) inhibitor AZD5305 has been accepted by the State Food and Drug Administration .
-
Amgen Flt3xCD3 dual anti-phase I clinical suspension of BCMxCD3 dual anti-phase I clinical recovery
Time of Update: 2021-08-29
In December 2014, Amgen's CD19xCD3 bispecific antibody blinatumomab (blinatumomab; indication for acute lymphoblastic leukemia) was approved by the FDA for marketing, opening a new phase in the development of dual antibodies .
-
National Medical Insurance Administration: Accelerate the advancement of traditional Chinese medicine and formula particles into centralized procurement
Time of Update: 2021-08-29
4126 of the Fourth Session of the 13th National People's Congress, and received the recommendation made by Representative Lu Qingguo on accelerating the entry of traditional Chinese medicine and formula granules into centralized procurement.
-
Lifang Pharmaceutical appointed Ms. Wang Qing as deputy general manager and elected as a non-independent director
Time of Update: 2021-08-28
Wang Qing as a non-independent director of the fourth board of directors.
The term of office is from the date of approval by the company’s general meeting of shareholders to the expiration of the company’s fourth board of directors.
-
Up to 800%!
Time of Update: 2021-08-28
According to statistics from the WeChat public account "Yao Chunqiu", 4 nationally sourced varieties entered the ranking of the top 50 domestic annual growth varieties, namely: Engligliflozin tablets, Olanzapine orally disintegrating tablets, and Tofacitib citrate tablets.
Olanzapine orally disintegrating tablets (enter the third batch of national procurement in August 2020)The sales scale has increased from RMB 227.
-
Fosun Pharma Holding Subsidiary's Trastuzumab for Injection Obtained Notice of Approval of Supplementary Drug Application
Time of Update: 2021-08-28
On August 17, Fosun Pharma issued an announcement stating that its controlling subsidiary Hanlius Pharmaceuticals had received the "Drug Supplementary Application for Trastuzumab for Injection (trade name: Hanquyou®) issued by the National Medical Products Administration.
-
How to prescribe long-term prescription drugs?
Time of Update: 2021-08-28
However, the "Specifications" also clearly emphasized that medical toxic drugs, radioactive drugs, precursor drugs, narcotic drugs, Class I and Class II psychotropic drugs, and antimicrobial drugs (for the treatment of chronic bacterial and fungal infectious diseases such as tuberculosis ) Except medicines), and medicines with special requirements for storage conditions shall not be used for long-term prescriptions .
-
Is Israel's new drug EXO-CD24 the hope of ending the new coronavirus?
Time of Update: 2021-08-28
The main reason for the death of patients with the new coronavirus infection is the strong pulmonary immune response-or cytokine storm .
-
Three products of Shuoshi Biotech have been certified by the Saudi Arabian Food and Drug Administration
Time of Update: 2021-08-28
Nucleic acid rapid extraction reagent (magnetic bead method): used to extract and purify viral nucleic acid from serum, plasma, virus culture fluid and other samples; certification number: ME0000001055SFDAA00025; expiration date: August 13, 2021-2024 May 27th3.
